American Association for Cancer Research

Skip to Main Content

Table 3

Summary of steady-state concentrations of ISIS 3521 and ISIS 5132^a

Agent	Sample day	No. patients	Parent oligonucleotide (μg/ml)	Total oligonucleotide (μg/ml)	% Intact
ISIS 3521	8	7	0.92 ± 0.37	1.70 ± 0.74	54.27 ± 4.07
	15	8	0.98 ± 0.61	1.78 ± 1.00	54.51 ± 6.37
	22	7	0.76 ± 0.27	1.42 ± 0.66	56.05 ± 9.79
Mean Css^b			0.89 ± 0.43	1.65 ± 0.79
ISIS 5132	8	7	0.73 ± 0.34	1.20 ± 0.64	61.88 ± 7.94
	15	11	0.61 ± 0.33	1.08 ± 0.56	57.46 ± 10.31
	22	11	0.60 ± 0.30	1.05 ± 0.57	58.14 ± 11.48
Mean Css^b			0.63 ± 0.31	1.10 ± 0.57

Agent	Sample day	No. patients	Parent oligonucleotide (μg/ml)	Total oligonucleotide (μg/ml)	% Intact
ISIS 3521	8	7	0.92 ± 0.37	1.70 ± 0.74	54.27 ± 4.07
	15	8	0.98 ± 0.61	1.78 ± 1.00	54.51 ± 6.37
	22	7	0.76 ± 0.27	1.42 ± 0.66	56.05 ± 9.79
Mean Css^b			0.89 ± 0.43	1.65 ± 0.79
ISIS 5132	8	7	0.73 ± 0.34	1.20 ± 0.64	61.88 ± 7.94
	15	11	0.61 ± 0.33	1.08 ± 0.56	57.46 ± 10.31
	22	11	0.60 ± 0.30	1.05 ± 0.57	58.14 ± 11.48
Mean Css^b			0.63 ± 0.31	1.10 ± 0.57

^a

Values represent means (± SD).

^b

Mean Css, average concentration of days 8, 15, and 22.